1,023名女性首次辅助生殖技术治疗期间的生活质量及心理社会与身体健康:比较促性腺激素释放激素拮抗剂与激动剂方案的随机对照试验次要结局
该研究为前瞻性4期开放标签随机对照试验的次要结局分析,纳入1,023名首次接受辅助生殖技术治疗的女性,1:1随机分配至短效GnRH拮抗剂方案(528例)或长效GnRH激动剂方案(495例)。结果显示拮抗剂组在心理社会和身体健康多个条目上评分优于激动剂组,但自报总体生活质量两组相似且略低于正常。
要点
- 拮抗剂组情感更少(AOR 0.69)、日常活动受限更少(AOR 0.74)、意外哭泣更少(AOR 0.71)、睡眠质量更好(AOR 1.55)。
- 激动剂组身体健康感受更差。
- 两组自报总体生活质量评分相似且略低于正常。
核心结论
- 短效GnRH拮抗剂方案组女性在首次辅助生殖技术治疗期间的心理社会和身体健康评分优于长效GnRH激动剂方案组,但自报总体生活质量单一条目两组评分相似。
研究设计与样本
- 前瞻性4期开放标签随机对照试验的次要结局分析,1,023名首次接受辅助生殖技术治疗的女性按1:1随机分配至短效GnRH拮抗剂方案(528例)或长效GnRH激动剂方案(495例)。
- 治疗期间完成四次身体健康自报问卷,在hCG检测日完成生活质量和心理社会健康自报问卷。
主要发现
- 问卷应答率在GnRH拮抗剂组为79.4%,在GnRH激动剂组为74.3%。
- GnRH拮抗剂组相比GnRH激动剂组:感到更少情绪化(AOR 0.69)、日常活动受限更少(AOR 0.74)、意外哭泣更少(AOR 0.71)、睡眠质量评分更好(AOR 1.55)。
- 接受GnRH激动剂治疗的女性身体健康感受更差。
- 两组自报总体生活质量评分相似且略低于正常。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare self-reported quality of life, psychosocial well-being, and physical well-being during assisted reproductive technology (ART) treatment in 1,023 women allocated to either a short GnRH antagonist or long GnRH agonist protocol. DESIGN: Secondary outcome of a prospective phase 4, open-label, randomized controlled trial. Four times during treatment a questionnaire on self-reported physical well-being was completed. Further, a questionnaire on self-reported quality of life and psychosocial well-being was completed at the day of hCG testing. SETTING: Fertility clinics at university hospitals. PATIENT(S): Women referred for their first ART treatment were randomized in a 1:1 ratio and started standardized ART protocols. INTERVENTION(S): Gonadotropin-releasing hormone analogue; 528 women allocated to a short GnRH antagonist protocol and 495 women allocated to a long GnRH agonist protocol. MAIN OUTCOME MEASURE(S): Self-reported quality of life, psychosocial well-being, and physical well-being based on questionnaires developed for women receiving ART treatment. RESULT(S): Baseline characteristics were similar, and response rates were 79.4% and 74.3% in the GnRH antagonist and GnRH agonist groups, respectively. Self-reported quality of life during ART treatment was rated similar and slightly below normal in both groups. However, women in the GnRH antagonist group felt less emotional (adjusted odds ratio [AOR] 0.69), less limited in their everyday life (AOR 0.74), experienced less unexpected crying (AOR 0.71), and rated quality of sleep better (AOR 1.55). Further, women receiving GnRH agonist treatment felt worse physically. CONCLUSION(S): Women in a short GnRH antagonist protocol rated psychosocial and physical well-being during first ART treatment better than did women in a long GnRH agonist protocol. However, the one item on self-reported general quality of life was rated similarly. CLINICAL TRIAL REGISTRATION NUMBER: NCT00756028.
引用
- Toftager M, Sylvest R, Schmidt L, et al. Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols. Fertil Steril. 2017. PMID: 29175067. doi:10.1016/j.fertnstert.2017.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。